Publicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (27)

2023

  1. Molecular Pathology of Endometrial Tumors

    Molecular Surgical Pathology: Second Edition (Springer International Publishing), pp. 297-321

2022

  1. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma

    Molecular Oncology, Vol. 16, Núm. 11, pp. 2235-2259

  2. M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors

    British Journal of Cancer

  3. Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer

    Cancers, Vol. 14, Núm. 12

2021

  1. Autophagy in the physiological endometrium and cancer

    Autophagy, Vol. 17, Núm. 5, pp. 1077-1095

2020

  1. Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study

    Histopathology, Vol. 76, Núm. 3, pp. 447-460

  2. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma

    Journal of Investigative Dermatology, Vol. 140, Núm. 6, pp. 1253-1265

2019

  1. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma

    Virchows Archiv, Vol. 474, Núm. 5, pp. 585-598

  2. Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis

    Journal of Pathology, Vol. 247, Núm. 1, pp. 72-85

2018

  1. Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences

    Pathobiology, Vol. 85, Núm. 1-2, pp. 35-40

2017

  1. Endometrial carcinoma: Specific targeted pathways

    Advances in Experimental Medicine and Biology (Springer New York LLC), pp. 149-207

2016

  1. Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism

    Oncotarget, Vol. 7, Núm. 32, pp. 52364-52374

2015

  1. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model

    Methods, Vol. 77, pp. 31-40

2014

  1. Combinatorial therapy using dovitinib and ICI182.780 (Fulvestrant) blocks tumoral activity of endometrial cancer cells

    Molecular Cancer Therapeutics, Vol. 13, Núm. 4, pp. 776-787

2013

  1. Three-dimensional epithelial cultures: A tool to model cancer development and progression

    Histology and Histopathology, Vol. 28, Núm. 10, pp. 1245-1256

2012

  1. ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFα and IL1α in lumen formation and maintenance

    Journal of Cell Science, Vol. 125, Núm. 8, pp. 1929-1944

2011

  1. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels

    American Journal of Pathology, Vol. 178, Núm. 4, pp. 1529-1543

  2. Nuclear factor-B2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner

    Laboratory Investigation, Vol. 91, Núm. 6, pp. 859-871

2010

  1. A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis

    American Journal of Pathology, Vol. 176, Núm. 6, pp. 2722-2731

  2. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

    European Journal of Cancer, Vol. 46, Núm. 4, pp. 836-850